Relation between intact fibroblast growth factor 23 and renal anemia in maintenance hemodialysis patients

HAN Bei; HAN Junling; CAO Jinghao; YU Yang; GONG Qin

doi:10.7619/jcmp.20213812

Journal of Clinical Medicine in Practice > 2021 > 25(21): 114-118. > DOI: 10.7619/jcmp.20213812

HAN Bei, HAN Junling, CAO Jinghao, YU Yang, GONG Qin. Relation between intact fibroblast growth factor 23 and renal anemia in maintenance hemodialysis patients[J]. Journal of Clinical Medicine in Practice, 2021, 25(21): 114-118. DOI: 10.7619/jcmp.20213812

Citation:

PDF (813 KB)

Relation between intact fibroblast growth factor 23 and renal anemia in maintenance hemodialysis patients

1.
Department of Nephrology, Yangzhou Friendship Hospital, Yangzhou, Jiangsu, 225001
2.
Department of Clinical Laboratory, Taizhou People's Hospital in Jiangsu Province, Taizhou, Jiangsu, 225300
3.
Xinxiang Medical University, Xinxiang, Henan, 453000
4.
Department of General Practice, Taizhou People's Hospital in Jiangsu Province, Taizhou, Jiangsu, 225300

More Information

Received Date: September 22, 2021
Available Online: November 23, 2021
Published Date: November 14, 2021

Graphical Abstract

Abstract

Abstract

Objective To investigate the correlation between intact fibroblast growth factor 23 (iFGF23) and renal anemia in patients with maintenance hemodialysis (MHD).
Methods Subjects were screened according to inclusion and exclusion criteria, and their general information and laboratory examination data were collected. Serum iFGF23 of dialysis patients was detected by enzyme linked immunosorbent assay, and correlation and multiple linear regression analysis were performed.
Results A total of 138 MHD patients were included in this study. The overall hemoglobin (Hb) level was (105.0±19.0) g/L, and exceeded 110 g/L in 79 (57.2%) cases, with the standardization rate of renal anemia control of 57.2%. Patients were divided into two groups according to the standard of renal anemia control, and the level of iFGF23 in the standard group was lower than that in the non-standard group (P < 0.05). The level of Hb in MHD patients was positively correlated with erythrocyte volume (HCT), serum albumin (Alb), white blood cell (WBC) (P < 0.05), and negatively correlated with systolic blood pressure (SBP), serum creatinine (Scr), ferritin (Fer), and Ln(iFGF23) (P < 0.05). Multiple linear regression analysis showed that low serum Alb, high Scr, and high Ln (iFGF23) were independent predictors of renal anemia in MHD patients.
Conclusion Ln (iFGF23) is associated with risk of renal anemia in MHD patients, and its mechanism needs to be further elucidated.
- intact fibroblast growth factor 23,
- hemodialysis,
- renal anemia,
- creatinine,
- albumin

FullText(HTML)

References (19)

References

[1]	ECKARDT K U, AGARWAL R, ASWAD A, et al. Safety and efficacy of vadadustat for anemia in patients undergoing dialysis[J]. N Engl J Med, 2021, 384(17): 1601-1612. doi: 10.1056/NEJMoa2025956
[2]	BABITT J L, LIN H Y. Mechanisms of anemia in ckd[J]. J Am Soc Nephrol, 2012, 23(10): 1631-1634. doi: 10.1681/ASN.2011111078
[3]	PATEL N M, GUTIE RREZ O M, ANDRESS D L, et al. Vitamin D deficiency and anemia in early chronic kidney disease[J]. Kidney Int, 2010, 77(8): 715-720. doi: 10.1038/ki.2009.551
[4]	AGORO R, MONTAGNA A, GOETZ R, et al. Inhibition of fibroblast growth factor 23(FGF23) signaling rescues renal anemia[J]. FASEB J, 2018, 32(7): 3752-3764. doi: 10.1096/fj.201700667R
[5]	EDMONSTON D, WOLF M. FGF23 at the crossroads of phosphate, iron economy and erythropoiesis[J]. Nat Rev Nephrol, 2020, 16(1): 7-19. doi: 10.1038/s41581-019-0189-5
[6]	CHEN G, LIU Y, GOETZ R, et al. A-Klotho is a non-enzymatic molecular scaffold for FGF23 hormone signalling[J]. Nature, 2018, 553(7689): 461-466. doi: 10.1038/nature25451
[7]	TORO L, BARRIENTOS V, LEÓN P, et al. Erythropoietin induces bone marrow and plasma fibroblast growth factor 23 during acute kidney injury[J]. Kidney Int, 2018, 93(5): 1131-1141. doi: 10.1016/j.kint.2017.11.018
[8]	中国医师协会肾脏内科医师分会肾性贫血指南工作组. 中国肾性贫血诊治临床实践指南[J]. 中华医学杂志, 2021, 101(20): 1463-1502. doi: 10.3760/cma.j.cn112137-20210201-00309
[9]	FAUL C, AMARAL A P, OSKOUEI B, et al. FGF23 induces left ventricular hypertrophy[J]. J Clin Invest, 2011, 121(11): 4393-4408. doi: 10.1172/JCI46122
[10]	DAVID V, DAI B, MARTIN A, et al. Calcium regulates FGF-23 expression in bone[J]. Endocrinology, 2013, 154(12): 4469-4482. doi: 10.1210/en.2013-1627
[11]	MEIR T, DURLACHER K, PAN Z, et al. Parathyroid hormone activates the orphan nuclear receptor Nurr1 to induce FGF23 transcription[J]. Kidney Int, 2014, 86(6): 1106-1115. doi: 10.1038/ki.2014.215
[12]	BABITT J L, SITARA D. Crosstalk between fibroblast growth factor 23, iron, erythropoietin, and inflammation in kidney disease[J]. Curr Opin Nephrol Hypertens, 2019, 28(4): 304-310. doi: 10.1097/MNH.0000000000000514
[13]	DAVID V, MARTIN A, ISAKOVA T, et al. Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production[J]. Kidney Int, 2016, 89(1): 135-146. doi: 10.1038/ki.2015.290
[14]	TSAI M H, LEU J G, FANG Y W, et al. High fibroblast growth factor 23 levels associated with low hemoglobin levels in patients with chronic kidney disease stages 3 and 4[J]. Medicine: Baltimore, 2016, 95(11): e3049. doi: 10.1097/MD.0000000000003049
[15]	MEHTA R, CAI X, HODAKOWSKI A, et al. Fibroblast growth factor 23 and anemia in the chronic renal insufficiency cohort study[J]. Clin J Am Soc Nephrol, 2017, 12(11): 1795-1803. doi: 10.2215/CJN.03950417
[16]	GUTIÉRREZ O M, MANNSTADT M, ISAKOVA T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis[J]. N Engl J Med, 2008, 359(6): 584-592. doi: 10.1056/NEJMoa0706130
[17]	STEINMAN T I. Serum albumin: its significance in patients with ESRD[J]. Semin Dial, 2000, 13(6): 404-408. doi: 10.1046/j.1525-139x.2000.00110.x
[18]	YANG C, MENG Q, WANG H, et al. Anemia and kidney function decline among the middle-aged and elderly in China: a population-based national longitudinal study[J]. Biomed Res Int, 2020, 2020: 2303541. http://www.researchgate.net/publication/346103092_Anemia_and_Kidney_Function_Decline_among_the_Middle-Aged_and_Elderly_in_China_A_Population-Based_National_Longitudinal_Study/download
[19]	曹婧媛, 刘必成. 低氧诱导因子-脯氨酸羟化酶轴在肾性贫血中的作用机制研究进展[J]. 生理学报, 2018, 70(6): 623-629. https://www.cnki.com.cn/Article/CJFDTOTAL-SLXU201806006.htm

[1]	YU Yanlong, ZHANG Xinqi, LI Hu, LI Ning, YUAN Bo, CHEN Chao, ZHANG Zhuan. Effects of different deflation modes for endotracheal tube cuff on coughing response and hemodynamics during extubation[J]. Journal of Clinical Medicine in Practice, 2024, 28(9): 15-19, 24. DOI: 10.7619/jcmp.20232558
[2]	MA Rongrong, TIAN Shunping, SUN Jianhong, ZHANG Zhuan. Research progress of application of oxytocin in gynecological and obstetric surgery and its effect on hemodynamics[J]. Journal of Clinical Medicine in Practice, 2022, 26(3): 134-138. DOI: 10.7619/jcmp.20220294
[3]	ZHOU Yuan, CHEN Haiyan. Effect of different anesthesia methods on hemodynamics and immune function for patients with lung cancer[J]. Journal of Clinical Medicine in Practice, 2020, 24(24): 13-16. DOI: 10.7619/jcmp.202024004
[4]	ZHANG Zhian, LEI Guodong. Effect of combined spinal-epidural anesthesia versus general anesthesia on hemodynamics and stress response in patients with hip replacement[J]. Journal of Clinical Medicine in Practice, 2020, 24(13): 80-83. DOI: 10.7619/jcmp.202013023
[5]	ZHENG Ling, ZHU Chongjun. Effects of dexmedetomidine on hemodynamics, agitation in awaken period, and pain degree in pediatric anesthesia[J]. Journal of Clinical Medicine in Practice, 2020, 24(11): 62-64. DOI: 10.7619/jcmp.202011017
[6]	YAO Minglong, CHEN Xiaofei. Influence of different doses of dexmedetomidine on hemodynamics of pregnancy-induced hypertension syndrome patients with cesarean section[J]. Journal of Clinical Medicine in Practice, 2017, (5): 90-92,96. DOI: 10.7619/jcmp.201705025
[7]	LI Yinli. Influence of different dosage of dexmedetomidine combined with general anesthesia on hemodynamics and revival quality of patients[J]. Journal of Clinical Medicine in Practice, 2016, (21): 62-65. DOI: 10.7619/jcmp.201621019
[8]	WU Qian. Influence of general anesthesia combined with epidural anesthesiaon hemodynamics and levels of inflammatory factors in patients with open chest surgery[J]. Journal of Clinical Medicine in Practice, 2016, (7): 72-74,89. DOI: 10.7619/jcmp.201607021
[9]	HU Xuehong, DI Xueyuan, LIU Weidong. Influence of small dose and isobaric bupivacaine on hemodynamics and stress of patients with cesarean section by spinal-epidural anesthesia[J]. Journal of Clinical Medicine in Practice, 2015, (11): 54-56,60. DOI: 10.7619/jcmp.201511016
[10]	TAO Xueyou, LI Xiaoming, NING Ni, ZHAI Haixia, ZUO Meijuan. The effect of Dexmedetomidine on induction period of hemodynamics in patients undergoing general anesthesia combined with epidural block[J]. Journal of Clinical Medicine in Practice, 2014, (5): 125-126,132. DOI: 10.7619/jcmp.201405043

Cited By

Cited by

Periodical cited type(10)

1.	张伟. NT-proBNP、D-D、CRP检测在中老年急性脑梗死患者中的临床诊断价值分析. 中国实用医药. 2024(10): 81-84 .
2.	杨光，毛婷婷，陈红蕾，张海燕. 间质性肺疾病急性加重期患者外周血D-二聚体、B型钠尿肽的检测应用. 锦州医科大学学报. 2024(03): 61-65 .
3.	刘爱平. 动态检测D-二聚体浓度在急性脑梗死患者溶栓治疗中的意义. 中国实用医药. 2023(05): 89-91 .
4.	孙培丽，孙贵祥，许秀兰. 急性脑梗死静脉溶栓短期预后的影响因素分析. 北京医学. 2022(03): 209-212 .
5.	张洁菁，余小萍，沈捷玉. cTnⅠ、Mb、D-D、Hcy水平变化与急性脑梗死患者预后的相关性研究. 黑龙江医药. 2021(02): 447-449 .
6.	李海燕，肖瑾，刘兵荣，吴婷. 凝血酶原时间、活化部分凝血酶原时间、纤维蛋白原、C反应蛋白、脑钠肽检测对急性脑梗死诊断价值研究. 临床军医杂志. 2020(02): 219-221 .
7.	刘芳卉. 急性大面积脑梗死患者的临床急救护理措施探讨. 心理月刊. 2020(07): 123 .
8.	林梓波. 血清指标因子在急性脑梗死治疗前后的评估意义. 黑龙江医药. 2020(04): 933-934 .
9.	俞峰，郑毅敏，张帅，吴峰. 血清可溶性肿瘤坏死因子样弱凋亡诱导因子、B型利钠肽、基质金属蛋白酶1水平与扩张型心肌病患者左心室重构的关系. 中国基层医药. 2020(12): 1472-1476 .
10.	王珏，孙杰，徐乾治. 急性脑梗死患者的血浆D-二聚体和N末端B型钠尿肽前体水平及其意义分析. 内科. 2020(05): 592-593+610 .

Other cited types(1)

Get Citation

PDF

XML

Article views PDF downloads Cited by(11)

Turn off MathJax

Article Contents

Abstract

References

Relation between intact fibroblast growth factor 23 and renal anemia in maintenance hemodialysis patients